國家衛生研究院 NHRI:Item 3990099045/9279
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 915571      Online Users : 1264
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9279


    Title: Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: A case report
    Authors: Su, YY;Chiang, NJ;Wu, CC;Chen, LT
    Contributors: National Institute of Cancer Research
    Abstract: The majority of gastrointestinal stromal tumors (GISTs) arise in the stomach and small intestine; primary GIST of the liver is extremely rare. GISTs share specific immunohistological features with melanoma, therefore, determining a definitive diagnosis can be difficult. However, electron microscopy can be used to aid the differential diagnosis of GIST. The present study reports the first case of a KIT/platelet‑derived growth factor receptor α (PDGFRA) wild‑type, primary GIST arising from the liver in a long‑term survivor of anorectal melanoma. The patient underwent APR for treatment of malignant melanoma of the anorectum in 2001 with no adjuvant therapy and remained disease-free until 2009. In 2009, the patient presented with a solitary, rapidly growing hypervascular liver tumor, which was subsequently diagnosed as a primary GIST of the liver. Imatinib treatment (400 mg/day) was initially administered for two months, however, disease progression occurred. Therefore, the patient underwent chemotherapy with doxorubicin (50 mg/m2) and cisplatin (50 mg/m2) every three weeks. Although this temporarily resulted in stable disease, progression occurred five months later. Finally, oral sunitinib (37.5 mg/day) was administered; however, the patient succumbed to the disease one month later. Despite the current GIST patient exhibiting a poor response to imatinib, the present study highlights the importance of considering a second primary malignancy and performing immunohistochemical analysis upon the occurrence of a newly developed lesions in long‑term remission cancer survivors.
    Date: 2015-08
    Relation: Oncology Letters. 2015 Aug;10(4):2366-2370.
    Link to: http://dx.doi.org/10.3892/ol.2015.3561
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1792-1074&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000362999500075
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84940041403
    Appears in Collections:[Li-Tzong Chen] Periodical Articles
    [Nai-Jung Chiang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    SCP84940041403.pdf1013KbAdobe PDF501View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback